107 related articles for article (PubMed ID: 18057715)
1. Analyses of novel prognostic factors in neuroblastoma patients.
Ootsuka S; Asami S; Sasaki T; Yoshida Y; Nemoto N; Shichino H; Chin M; Mugishima H; Suzuki T
Biol Pharm Bull; 2007 Dec; 30(12):2294-9. PubMed ID: 18057715
[TBL] [Abstract][Full Text] [Related]
2. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
3. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
[TBL] [Abstract][Full Text] [Related]
4. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas.
Zhang J; Zheng Y; Wang Y; Tong H
J Pediatr Hematol Oncol; 2010 Apr; 32(3):180-4. PubMed ID: 20186105
[TBL] [Abstract][Full Text] [Related]
5. Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors.
Beck D; Gross N; Brognara CB; Perruisseau G
Blood; 1995 Oct; 86(8):3132-8. PubMed ID: 7579408
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma.
Lee NH; Son MH; Choi YB; Yi E; Lee JW; Yoo KH; Sung KW; Koo HH
Cancer Res Treat; 2016 Oct; 48(4):1399-1407. PubMed ID: 27034145
[TBL] [Abstract][Full Text] [Related]
8. Significance of survivin mRNA expression in prognosis of neuroblastoma.
Ito R; Asami S; Motohashi S; Ootsuka S; Yamaguchi Y; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2005 Apr; 28(4):565-8. PubMed ID: 15802787
[TBL] [Abstract][Full Text] [Related]
9. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.
Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP
Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914
[TBL] [Abstract][Full Text] [Related]
10. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
11. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
Uccini S; Mannarino O; McDowell HP; Pauser U; Vitali R; Natali PG; Altavista P; Andreano T; Coco S; Boldrini R; Bosco S; Clerico A; Cozzi D; Donfrancesco A; Inserra A; Kokai G; Losty PD; Nicotra MR; Raschellà G; Tonini GP; Dominici C
Clin Cancer Res; 2005 Jan; 11(1):380-9. PubMed ID: 15671569
[TBL] [Abstract][Full Text] [Related]
13. Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis--a study of 106 primary neuroblastomas treated in a single institute.
Hishiki T; Saito T; Terui K; Sato Y; Takenouchi A; Yahata E; Ono S; Nakagawara A; Kamijo T; Nakamura Y; Matsunaga T; Yoshida H
J Pediatr Surg; 2010 Dec; 45(12):2293-8. PubMed ID: 21129533
[TBL] [Abstract][Full Text] [Related]
14. Classification of neuroblastomas based on an analysis of the expression of genes related to prognosis.
Tajiri T; Higashi M; Souzaki R; Tatsuta K; Kinoshita Y; Taguchi T
J Pediatr Surg; 2007 Dec; 42(12):2046-9. PubMed ID: 18082705
[TBL] [Abstract][Full Text] [Related]
15. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year.
Burchill SA; Lewis IJ; Abrams KR; Riley R; Imeson J; Pearson AD; Pinkerton R; Selby P
J Clin Oncol; 2001 Mar; 19(6):1795-801. PubMed ID: 11251011
[TBL] [Abstract][Full Text] [Related]
16. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Ki-67 as prognostic factor for pediatric neuroblastoma and the possibility of molecular-targeted drugs with VEGF and PDGFR.
Watanabe S; Suzuki T; Kondo Y; Naoe A; Uga N; Yasui T; Hara F; Tsuchiya T
Minerva Pediatr (Torino); 2023 Aug; 75(4):561-566. PubMed ID: 30605998
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma.
Ito R; Asami S; Kagawa S; Motohashi S; Shichino H; Chin M; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2004 Mar; 27(3):315-8. PubMed ID: 14993794
[TBL] [Abstract][Full Text] [Related]
20. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
